• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

OMRF is an independent, nonprofit biomedical research institute dedicated to discoveries that make a difference.

  • About
    • General Information
    • Disease Research
    • Education & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti-Aging Studies
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Tax Credit
    • Planned Giving
    • Vehicle Donations
    • Why We Give
    • Your Gift at Work
    • Donor Recognition
    • Contact
Home - OMRF News - Archives for chuck esmon

chuck esmon

OMRF enters into a license agreement with Shanghai RAAS Blood Products

February 13, 2018

OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.

Filed Under: News, Technology Ventures News Tagged With: Activated Protein C, agreement, americans, antibody, apc, approval, blood, blood clots, breakthrough, CDC, Charles, charles esmon, China, chuck esmon, deal, death, disorder, drug, Esmon, forbes, hemophilia, injuries, innovation, license, Manu Nair, new, news, newsok, novel, OKC, Oklahoma City, Oklahoma Medical Research Foundation, OMRF, products, research, rights, scientist-news, sepsis, shanghai raas, technology, trauma, traumatic bleeding, treatment

OMRF collaborates with GSK to develop novel treatments for severe inflammatory diseases

July 24, 2017

This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.

Filed Under: News, Technology Ventures News Tagged With: acute pancreatitis, agreement, blood, business, Charles, charles esmon, chuck esmon, collaboration, company, death, discovery partnerships with academia, dpas, drug, Esmon, Florea, Florea Lupu, gsk, healthcare, histones, lung injury, Lupu, newsok, nonprofit, novel, OKC, Oklahoma City, Oklahoma Medical Research Foundation, OMRF, organ damage, padmaja mehta-D-souza, partner, research, scientist-news, scientists, therapy, toxic, trauma

OMRF shares in $23.8 million grant to research trauma

November 15, 2013

Trauma is a leading cause of death in people under age 34.

Filed Under: Diseases, Featured News, News, Research News Tagged With: blood, Charles, charles esmon, chuck esmon, clotting, coagulation, coagulopathy, Department of Defense, Esmon, Kenneth Mann, NHLBI, scientist-news, Stephen Wisniewski, TACTIC, Trans-Agency Consortium for Trauma-Induced Coagulopathy, trauma, traumatic injury

Activated Protein C might protect kidneys from diabetes

January 8, 2013

Increased ACP could slow or stop diabetic nephropathy, which kills kidney cells.

Filed Under: Featured News, News Tagged With: Activated Protein C, Charles, charles esmon, chuck esmon, diabetes, diabetic nephropathy, Dr. Death, Esmon, kidney, kidney failure, OMRF, p66, scientist-news, thrombomodulin

Meagan’s Miracle

We have a drug we think might help your daughter, they said.

Pages: Page 1 Page 2 Page 3

Prayers, Answered

An Oklahoman suffering from a life-threatening disease.

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7
  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Before Footer

EEO/AA Employer/Vet/Disabled

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayGive Smart OKCTop Workplace